The Effect of proteolysis-targeting chimera (PROTAC) of EZH2 on high grade Serous ovarian Carcinoma.

被引：0
|
作者：
Hachijo, Ryuta [1 ]
Sone, Kenbun [1 ]
Jonouchi, Yuri [1 ]
Ishizaka, Aya [1 ]
Suzuki, Eri [1 ]
Tsuchimochi, Saki [1 ]
Tanimoto, Saki [1 ]
Toyohara, Yusuke [1 ]
Honjo, Harunori [1 ]
Fukuda, Tomohiko [1 ]
Miyamoto, Yuichiro [1 ]
Mori, Mayuyo [1 ]
Oda, Katsutoshi [2 ]
Hirota, Yasushi [1 ]
Osuga, Yutaka [1 ]
机构：
[1] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Univ Tokyo, Dept Clin Genom, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3205
引用
收藏
页码：1685 / 1685
页数：1
相关论文
共 50 条
  • [1] EZH2 Expression in High-Grade Ovarian Serous Carcinoma and Resistance to Therapy
    Reid, Brett
    Saglam, Ozlen
    Permuth, Jennifer
    Sellers, Thomas
    LABORATORY INVESTIGATION, 2019, 99
  • [2] EZH2 Expression in High-Grade Ovarian Serous Carcinoma and Resistance to Therapy
    Reid, Brett
    Saglam, Ozlen
    Permuth, Jennifer
    Sellers, Thomas
    MODERN PATHOLOGY, 2019, 32
  • [3] CLINICAL OUTCOMES ASSOCIATED WITH EZH2 EXPRESSION IN HIGH-GRADE OVARIAN SEROUS CARCINOMA
    Saglam, O.
    Vyas, S.
    Reid, B.
    Permuth, J.
    Sellers, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A135 - A135
  • [4] Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
    Reid, Brett M.
    Vyas, Shraddha
    Chen, Zhihua
    Chen, Ann
    Kanetsky, Peter A.
    Permuth, Jennifer B.
    Sellers, Thomas A.
    Saglam, Ozlen
    BMC CANCER, 2021, 21 (01)
  • [5] Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
    Brett M. Reid
    Shraddha Vyas
    Zhihua Chen
    Ann Chen
    Peter A. Kanetsky
    Jennifer B. Permuth
    Thomas A. Sellers
    Ozlen Saglam
    BMC Cancer, 21
  • [6] EZH2 Expression Correlates with Increased Angiogenesis in Ovarian Carcinoma.
    Albashiti, B.
    Sood, A.
    Bandyopadhyay, S.
    Semaan, A.
    Munkarah, A.
    Hussein, Y.
    Ahmed, Q.
    Morris, R.
    Ali-Fehmi, R.
    MODERN PATHOLOGY, 2011, 24 : 234A - 234A
  • [7] EZH2 Expression Correlates with Increased Angiogenesis in Ovarian Carcinoma.
    Ahmed, Y.
    Nasser, H.
    Al-Hajeili, M.
    Kuntzman, T.
    Albashiti, B.
    Ali-Fehmi, R.
    Mazzara, P.
    Fathallah, L.
    LABORATORY INVESTIGATION, 2011, 91 : 234A - 234A
  • [8] Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma
    Han, Ye
    Wei, Yongkun
    Yao, Jun
    Chu, Yu-Yi
    Li, Chia-Wei
    Hsu, Jennifer L.
    Nie, Lei
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (04): : 1194 - +
  • [9] A NEW PRIMARY PREVENTION STRATEGY FOR HIGH GRADE SEROUS "OVARIAN" CARCINOMA.
    Beirne, J.
    Quinn-O'Brien, J.
    McCabe, N.
    Mcart, D.
    Salto-Tellez, M.
    Kennedy, R.
    Harley, I.
    McCluggage, G.
    Mullan, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 587 - 587
  • [10] Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
    Spiliopoulou, Pavlina
    Spear, Sarah
    Mirza, Hasan
    Garner, Ian
    McGarry, Lynn
    Grundland-Freile, Fabio
    Cheng, Zhao
    Ennis, Darren P.
    Iyer, Nayana
    McNamara, Sophie
    Natoli, Marina
    Mason, Susan
    Blyth, Karen
    Adams, Peter D.
    Roxburgh, Patricia
    Fuchter, Matthew J.
    Brown, Bob
    McNeish, Iain A.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 522 - 534
12345